NCT07305740 On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety
| NCT ID | NCT07305740 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Dana-Farber Cancer Institute |
| Condition | Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2026-03-11 |
| Primary Completion | 2027-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2026-03-11 with a primary completion date of 2027-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is evaluating On-Trac (Online Training After Cancer), an online educational intervention to teach adult cancer survivors strategies to address anxiety based on Cognitive-Behavioral Therapy (CBT) and Acceptance Commitment Therapy (ACT) The name of the study intervention is Online Training After Cancer (On-Trac)
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 * A diagnosis of cancer (except non-melanoma skin cancer) ≥ 12 months prior. * No active cancer therapy (excluding chemoprevention) in the past 4 months, and no further therapy planned. * Significant anxiety as evidenced by both of the following * Endorsement of the SCID ( Structured Clinical Interview for the DSM-5) Screener Items for Social Anxiety Disorder, Generalized Anxiety Disorder, Agoraphobia, Specific Phobia, or Illness Anxiety Disorder. * A score ≥ 6 on the Overall Anxiety Severity and Impairment Scale (OASIS). * Regular access to the internet. * Ability to read and write in English. Exclusion Criteria: * Significant symptoms of Panic Disorder in the prior month, including anticipatory anxiety of having a future panic attack or avoidance symptoms associated with panic attacks, as assessed by three SCID-5 items from the panic attack disorder module. * Significant symptoms of Obsessive Compulsive Disorder, as evidenced by any obsessions over the past 3 months, as assessed by three SCID items from the Obsessive Compulsive Disorder module. * Psychiatric hospitalizations or emergency room visits for psychiatric care in the prior 2 years. * In the next two months, intention to use or likelihood of using emergent or "rescue" anxiety medication (e.g., Ativan, Xanax, Valium) or self-prescribed substances (i.e., marijuana) at the onset of anxiety symptoms or when entering a situation where they expect to experience anxiety. * Any significant marijuana use which could impact anxiety symptoms, as evidenced by one of the following: * 4 days of marijuana use in any week in the last month * 20 milligrams of THC (Tetrahydrocannabinol) products in any week in the last month. * Participation in any CBT or ACT-based behavioral or education intervention for anxiety in the past 2 years. This includes in-person, asynchronous, and synchronous online anxiety programs, and therapy that includes these skills. This does not include independent use of any self-help materials (i.e., workbooks, books). * Any impairment (e.g., hearing, visual, cognitive) that interferes with the ability to complete all parts of the study independently.
Contact & Investigator
Christopher J Recklitis, PhD, MPH
PRINCIPAL INVESTIGATOR
Dana-Farber Cancer Institute
Frequently Asked Questions
Who can join the NCT07305740 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07305740 currently recruiting?
Yes, NCT07305740 is actively recruiting participants. Contact the research team at ontrac@dfci.harvard.edu for enrollment information.
Where is the NCT07305740 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT07305740 clinical trial?
NCT07305740 is sponsored by Dana-Farber Cancer Institute. The principal investigator is Christopher J Recklitis, PhD, MPH at Dana-Farber Cancer Institute. The trial plans to enroll 80 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.